BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
April 12 2021 - 5:30AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)
(TSX-V:BCT) (“BriaCell” or the “Company”), a
clinical-stage biotechnology company specializing in targeted
immunotherapies for advanced breast cancer, is pleased to announce
the presentation of results from clinical studies with its lead
product candidate, Bria-IMT™, summarized in a poster session held
at the American Association for Cancer Research (AACR) Annual
Meeting 2021, a virtual meeting, held over two weeks (Week 1: April
10-15; Week 2: May 17-21).
The findings indicate disease control in
advanced breast cancer patients, including stable disease (SD),
partial responses (PR) or complete responses (CR). Disease control
was especially noted in patients with Grade I/II (i.e. well or
moderately differentiated) tumors or those that matched Bria-IMT™
at 2 or more HLA alleles. Patients with low or undetectable levels
of circulating cancer cells were more likely to benefit from
therapy.
Patients were treated with the Bria-IMT™ regimen
alone (i.e. monotherapy study) or the Bria-IMT™ regimen in
combination with immune checkpoint inhibitors, including
pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.),
and, more recently, Incyte’s retifanlimab (INCMGA00012, under a
corporate collaboration with Incyte Corporation). Dr. Bill
Williams, BriaCell’s President & CEO, presented the results of
the clinical and pathological analysis. The patient data summarized
and discussed belong to previously disclosed patients (i.e., no
incremental numbers enrolled).
Details and results on the poster presentation
are summarized below:
Poster Title:
Predictors of response to a modified whole tumor cell immunotherapy
in patients with advanced breast cancer from two phase I/IIa
trials
Analysis and
Discussion:
- The Bria-IMT™ regimen with or
without checkpoint inhibitors is able to induce an effective immune
response and disease control in heavily pre-treated advanced breast
cancer patients. The patients were all heavily pretreated and
failed multiple prior regimens.
- Delayed Type Hypersensitivity (DTH)
to Bria-IMT™ analysis identified a group with significantly higher
rates of disease control and progression-free survival (8 months)
in both monotherapy and combination therapy studies suggesting a
robust immune response is predictive of clinical benefit in these
patients.
- Highest levels of disease control
and PFS was observed in patients who matched Bria-IMT™ at 2 or more
HLA alleles in the monotherapy study but not in the combination
therapy study supporting our strategy to develop Bria-OTS™, an
off-the-shelf personalized immunotherapy for advanced breast
cancer.
- Patients with Grade I/II tumors
(median of 8 prior therapy regimens) were more likely to respond
with disease control (67%) and longer progression free survival.
The response was more pronounced in the patients in the combination
therapy study suggesting additive or synergistic effects of
checkpoint inhibitors when combined with the Bria-IMT™ regimen.
Bria-IMT™, with a molecular signature most closely related to Grade
I/II tumors, may result in disease control and clinical benefit
especially in this subset of patients.
A copy of the poster is posted at the
following: https://briacell.com/novel-technology/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Forward Looking Statements
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully in the section titled “Risk Factors” in the Company’s
SEC filings. Forward-looking statements contained in this
announcement are made as of this date, and BriaCell Therapeutics
Corp. undertakes no duty to update such information except as
required under applicable law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
Company Contact:William V. Williams,
MDPresident & CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamDirector of Public
RelationsCORE IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024